1289620-49-0Relevant academic research and scientific papers
Potent inhibitors of LpxC for the treatment of gram-negative infections
Brown, Matthew F.,Reilly, Usa,Abramite, Joseph A.,Arcari, Joel T.,Oliver, Robert,Barham, Rose A.,Che, Ye,Chen, Jinshan Michael,Collantes, Elizabeth M.,Chung, Seung Won,Desbonnet, Charlene,Doty, Jonathan,Doroski, Matthew,Engtrakul, Juntyma J.,Harris, Thomas M.,Huband, Michael,Knafels, John D.,Leach, Karen L.,Liu, Shenping,Marfat, Anthony,Marra, Andrea,McElroy, Eric,Melnick, Michael,Menard, Carol A.,Montgomery, Justin I.,Mullins, Lisa,Noe, Mark. C.,O'Donnell, John,Penzien, Joseph,Plummer, Mark S.,Price, Loren M.,Shanmugasundaram, Veerabahu,Thoma, Christy,Uccello, Daniel P.,Warmus, Joseph S.,Wishka, Donn G.
, p. 914 - 923 (2012/03/27)
In this paper, we present the synthesis and SAR as well as selectivity, pharmacokinetic, and infection model data for representative analogues of a novel series of potent antibacterial LpxC inhibitors represented by hydroxamic acid 1a.
C-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS
-
Page/Page column 55-56, (2011/05/05)
The present invention is directed to a new class of hydroxamic acid derivatives, their use as LpxC inhibitors, and more specifically their use to treat bacterial infections.
